Qnasl beclomethasone dipropionate nasal aerosol: Additional Phase III data

Additional data from a double-blind, U.S. Phase III trial in 715 patients aged 6-11 showed that once-daily 80 and 160 µg Qnasl significantly improved patient-reported AM and PM instantaneous TNSS vs. placebo (p<0.01). Qnasl also significantly improved physician-assessed nasal symptom scores (PNSS) by 0.096 points (p<0.001) in the 80 µg arm and by 0.072 (p=0.004) in the 160 µg arm vs. placebo. Data were presented at the American College of Allergy, Asthma and Immunology meeting in Anaheim. ...